VOOZH about

URL: https://pubmed.ncbi.nlm.nih.gov/32209163/

⇱ Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 - PubMed

Clipboard, Search History, and several other advanced features are temporarily unavailable.
Skip to main page content
👁 Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

👁 Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Abstract

The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.

Keywords: COVID-19; SARS-CoV-2; antibodies; coronavirus; humoral immunity; immunofluorescence assay; microneutralisation test; western blotting; whole-genome sequencing.

PubMed Disclaimer

Conflict of interest statement

LS is a co-investigator in an unrelated study, for which THL has received research funding from GlaxoSmithKline Vaccines. The other authors report no potential conflicts of interest.

Figures

👁 Figure 1
Figure 1
Timeline of events around the first COVID-19 case imported to Finland, January–February 2020
👁 Figure 2
Figure 2
Immunofluorescence assay of serum samples, COVID-19 index case, Finland, January–February 2020
👁 Figure 3
Figure 3
Western blot of mock- and SARS-CoV-2 infected Vero E6 cells using patient serum collected 20 days after onset of symptoms, Finland, January–February 2020

References

    1. World Health Organization (WHO). Novel Coronavirus (2019-nCoV) Situation report - 1. Geneva: WHO, 21 Jan 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...
    1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). 10.2807/1560-7917.ES.2020.25.3.2000045 - DOI - PMC - PubMed
    1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-9. 10.1038/s41586-020-2008-3 - DOI - PMC - PubMed
    1. Korzyukov Y, Hetzel U, Kipar A, Vapalahti O, Hepojoki J. Generation of anti-boa immunoglobulin antibodies for serodiagnostic applications, and their use to detect anti-reptarenavirus antibodies in boa constrictor. PLoS One. 2016;11(6):e0158417. 10.1371/journal.pone.0158417 - DOI - PMC - PubMed
    1. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539-42. 10.1128/JCM.36.2.539-542.1998 - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources

Full text links
👁 Ingenta plc full text link
Ingenta plc Free PMC article
Cite
Send To

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.